Sensei Biotherapeutics (SNSE) News Today $0.54 +0.05 (+10.30%) (As of 09/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy ConferenceSeptember 4, 2024 | globenewswire.comSensei Biotherapeutics to Present at Upcoming ConferencesSeptember 4, 2024 | globenewswire.comSensei Biotherapeutics Inc (407.MU)August 22, 2024 | uk.finance.yahoo.comSensei Biotherapeutics Inc (SNSE)August 9, 2024 | uk.investing.comBuy Rating Affirmed for Sensei Biotherapeutics on Strong Financials and Promising Drug TrialsAugust 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN), Sensei Biotherapeutics (SNSE) and Annovis Bio (ANVS)August 7, 2024 | markets.businessinsider.comSNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024August 6, 2024 | investorplace.comSensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 6, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Jefferies Global Healthcare ConferenceMay 30, 2024 | globenewswire.comSNSE Sensei Biotherapeutics, Inc.May 28, 2024 | seekingalpha.comBuy Rating on Sensei Biotherapeutics: Innovations and Promising Clinical DevelopmentsMay 25, 2024 | markets.businessinsider.comSensei stock plunges 46% in wake of Phase 1 dataMay 24, 2024 | msn.comWhy Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?May 24, 2024 | investorplace.comSensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101May 23, 2024 | globenewswire.comStephens & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Overweight RecommendationMay 14, 2024 | msn.comBuy Rating Justified for Sensei Biotherapeutics Amidst Strong Pipeline and Financial StabilityMay 13, 2024 | markets.businessinsider.comSNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024May 9, 2024 | investorplace.comSensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | globenewswire.comSensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual MeetingApril 24, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual ConferenceApril 9, 2024 | globenewswire.comSensei Biotherapeutics CFO Erin Colgan to resignApril 4, 2024 | uk.investing.comSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor MicroenvironmentApril 4, 2024 | globenewswire.comSensei Biotherapeutics to Participate in the 3rd Annual VISTA SymposiumMarch 22, 2024 | globenewswire.comSensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific ConferencesMarch 6, 2024 | globenewswire.comBuy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical TrialsFebruary 29, 2024 | markets.businessinsider.comSensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsFebruary 28, 2024 | globenewswire.comSensei Biotherapeutics Announces Board Member Resignation and Consultant RoleFebruary 9, 2024 | msn.comSensei Biotherapeutics Streamlines Board, Appoints Interim ChairFebruary 9, 2024 | msn.comSensei Biotherapeutics to Present at Upcoming ConferencesFebruary 7, 2024 | finance.yahoo.comBuy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety DataJanuary 6, 2024 | markets.businessinsider.comSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesJanuary 4, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)December 4, 2023 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy RecommendationDecember 4, 2023 | msn.comSensei Biotherapeutics GAAP EPS of -$0.28 in-lineNovember 7, 2023 | msn.comSensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 7, 2023 | finance.yahoo.comSensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial ResultsNovember 7, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingNovember 3, 2023 | finance.yahoo.comSensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingOctober 25, 2023 | finance.yahoo.comRockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from NasdaqOctober 24, 2023 | bizjournals.comSensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023October 23, 2023 | finance.yahoo.comSensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®September 27, 2023 | finance.yahoo.comSensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceSeptember 21, 2023 | finance.yahoo.comSensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceSeptember 13, 2023 | finance.yahoo.comSNSE - Sensei Biotherapeutics, Inc.August 30, 2023 | uk.finance.yahoo.comSensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 3, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth ConferenceAugust 2, 2023 | finance.yahoo.comSensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”June 13, 2023 | finance.yahoo.comSensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid TumorsJune 1, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Jefferies Global Healthcare ConferenceMay 31, 2023 | finance.yahoo.comCitigroup Remains a Buy on Sensei Biotherapeutics (SNSE)May 10, 2023 | markets.businessinsider.com Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address The election trade you can't lose (Ad)Politics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends. Download my Dividend Calendar here SNSE Media Mentions By Week SNSE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNSE News Sentiment▼0.000.49▲Average Medical News Sentiment SNSE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNSE Articles This Week▼00▲SNSE Articles Average Week Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TXMD News XGN News CTSO News CVM News VHAQ News ATNM News VNRX News THTX News AVTE News PRPH News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNSE) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
